Media Outlet:
Boston Globe Publication Date:
Description:
In a new paper, Prof. Andrew Lo argues that the FDA should apply less stringent criteria when approving experimental drugs for terminal diseases that have few treatment options, writes Ed Silverman for The Boston Globe. “For terminal patients with no existing treatments, it seems to make sense to be more lenient,” says Lo.